NGC Update Service: March 23, 2015

National Guideline Clearinghouse (NGC)

March 23, 2015


New This Week

Guideline Summaries

American College of Emergency Physicians

Association of periOperative Registered Nurses

National Clinical Guideline Centre

Announcements

How to Participate

  • Submit guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
  • Suggest a guideline for possible inclusion: Submit your suggestions for evidence-based guidelines that you would like to see included in NGC.
  • Suggest a Guideline Synthesis topic: We welcome your suggestions for guideline synthesis topics!

Health Awareness Topics - March 2015

Conference News

  • The Agency for Healthcare Research and Quality (AHRQ) is excited to announce that its research conference will be held October 4–6, 2015, in Crystal City, VA. The conference will bring authorities in health care research and policy together to participate in sessions focused on addressing today's challenges in improving quality, safety, access and value in health care. Visit the conference home page for more information.
  • The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.

U.S. Food and Drug Administration (FDA) Advisories

  • March 10, 2015: Treanda (bendamustine hydrochloride) Solution by Teva: FDA is warning health care professionals not to use Treanda Injection (45 mg/0.5 mL or 180 mg/2 mL solution) with closed system transfer devices (CSTD), adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS). Most marketed CSTDs contain either polycarbonate or ABS and are not compatible with Treanda Injection (45 mg/0.5 mL or 180 mg/2 mL solution). FDA is requiring label changes for both the solution and the powder formulations of Treanda to reflect safe preparation information.
  • March 9, 2015: Chantix (varenicline): FDA is warning that the prescription smoking cessation medicine Chantix (varenicline) can change the way people react to alcohol. Interactions between alcohol and Chantix have resulted in some patients experiencing increased intoxicating effects of alcohol, sometimes associated with aggressive behavior and/or amnesia. In addition, rare accounts of seizures in patients treated with Chantix have been reported. FDA has approved changes to the Chantix label to warn about these risks.

NGC's Sister Resource

Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).